Ya Lan Lin

Dr. Ya Lan Lin

Cathay General Hospital, Taipei, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
BHBo-Ruei Huang
Bo-Ruei Huang
YLYa Lan Lin
Ya Lan Lin
CWChih-Kang Wan
Chih-Kang Wan
JWJiin-Torng Wu
Jiin-Torng Wu
CHChih-Yu Hsu
Chih-Yu Hsu
CHCheng-Hua Huang
Cheng-Hua Huang

26 September 2017 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
YLYa Lan Lin
Ya Lan Lin
KHKun-Long Hung
Kun-Long Hung
CLChiao‐Wei Lo
Chiao‐Wei Lo
Key Clinical Message: Cerebral salt wasting syndrome can occur in children with encephalitis. Clinicians should be aware of hyponatremia in patients who develop polyuria with the signs of dehydration and deteriorated consciousness. Furthermore, patients who present with status epilepticus or who are suspected to have high intracranial pressure may have an increased risk of cerebral salt wasting syndrome.

3 July 2022 in Children
Verified
Journal Article
Open access
PDF file
YLYa Lan Lin
Ya Lan Lin
YHYi-Li Hung
Yi-Li Hung
CSChung Min Shen
Chung Min Shen
YCYung-Chuan Chen
Yung-Chuan Chen
WHWu-Shiun Hsieh
Wu-Shiun Hsieh
Background/Objective: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a cardiac natriuretic hormone that cardiomyocytes release in response to ventricular stretch. It helps with the diagnosis of heart failure in adults, but this application in preterm infants has rarely been reported. This study aimed to evaluate whether NT-proBNP could be used for the early detection of reduced cardiac ejection fraction in preterm infants and the optimal timing for NT-proBNP assessment. Design/Methods: This prospective, single-center, observational study enrolled all preterm infants with NT-proBNP measurements from October 2014 to February 2022. They underwent echocardiographic examinations within 48 h of the NT-proBNP measurements. Reduced left ventricular ejection fraction was defined as below 60%. Receiver operator characteristic (ROC) curves were generated to assess the optimal NT-proBNP cutoff point for the early prediction of reduced cardiac ejection fraction. Results: A total of 68 preterm infants were enrolled, with a total of 134 NT-proBNP measurements being available for analysis. Reduced left ventricular ejection fraction was present in seven infants (10.3%) due to various underlying diseases. The NT-proBNP cutoff level for detecting reduced left ventricular ejection fraction was 9248 pg/mL, with 71.4% sensitivity and 60.8% specificity; the area under the curve was 0.623 (95% CI: 0.487~0.760). The threshold for the optimal postnatal age for applying NT-proBNP to detect reduced left ventricular ejection fraction was >2 days of life (AUC: 0.682; 95% CI: 0.518~0.845), with 70% sensitivity and 67.1% specificity. Conclusions: Although the NT-proBNP levels declined dramatically after birth, a NT-proBNP serum level of 9248 pg/mL might be helpful for the early detection of reduced ejection fraction in preterm infants, and the optimal age for detection was after 2 days of life.